ClinicalTrials.gg
TerminatedNCT04889040MORNINGSKYUpdated Jan 5, 2024Results posted

Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19

A Phase 3 interventional study of RO7496998 and Placebo in COVID-19, sponsored by Hoffmann-La Roche. Terminated at 50 sites in 12 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2024-01-05.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Why this study was terminated
Based on program revaluation and in agreement with the co-development partner the sponsor took the decision to terminate this study.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
216
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 75 studies in COVID-19 with a site in Japan — 10 open to participants now, 11 under way, 8 of them phase 3. COVID-19 · Japan.

Enrollment
41st of 59
216 · median 602
Started
2021
with 21 others
Phase 3
34 of 75
8 open now
Registered
36th of 75
by date

Among the 75 studies in COVID-19 with a site in Japan, this one is the 41st largest by enrollment of the 59 interventional ones that give a count, is one of 22 that started in 2021, is one of 34 in phase 3, and was the 36th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.

Browse COVID-19 studies →

Open to participants now

10 of the 75 studies in COVID-19 with a site in Japan are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in COVID-19 with a site in Japan, or all of them as a file.
02

Study summary

This study will evaluate the efficacy, safety, antiviral activity, and pharmacokinetics of study drug RO7496998 (AT-527) compared to placebo in non-hospitalized adult and adolescent participants with mild to moderate coronavirus disease 2019 (COVID-19) in the outpatient setting.

03

Conditions studied

  • COVID-19

Browse trials for

Keywords

  • Coronavirus Disease 2019; COVID-19; antiviral drug; SARS-CoV-2; Mild to Moderate COVID-19; antiviral efficacy
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Positive SARS-CoV-2 diagnostic test (RT-PCR or validated rapid antigen test) ≤72 hours prior to randomization
  • At least three of the following symptoms of at least moderate (score ≥2 as per COVID-19 Symptom Diary) intensity: nasal congestion or runny nose, sore throat, cough, shortness of breath, muscle or body aches, fatigue, headache, chills or sweats, feeling hot or feverish, nausea, vomiting, or diarrhea.
  • Has symptoms consistent with mild or moderate COVID-19, as determined by the investigator, with onset ≤5 days before dosing on Day 1

Exclusion criteria

Exclusion Criteria:

  • Clinical signs indicative of COVID-19 illness requiring hospitalization
  • Admitted to a hospital prior to randomization or is hospitalized (inpatient) at randomization due to COVID-19
  • In the opinion of the investigator, is likely to experience imminent deterioration and require hospitalization
  • Treatment with an drug within 5 half-lives or 3 months (whichever is longer) of randomization
  • Treatment with a COVID-19 therapeutic agent including, but not limited to, other direct or indirect acting antivirals against SARS-CoV-2 (such as remdesivir or favipiravir), systemic or inhaled (such as dexamethasone or inhaled budesonide), colchicine, ivermectin, interferons, convalescent plasma, monoclonal antibodies against SARS CoV-2 or interleukin 6 (IL-6), intravenous immunoglobulin or other EUA-approved treatments within 3 months or less than 5 drug elimination half-lives (whichever is longer) prior to the screening visit
  • Concomitant use of P-glycoprotein inhibitors or inducers listed as prohibited therapy in the protocol
  • Known allergy or to components of study drug
  • Abnormal laboratory test results at screening
  • Requirement of any prohibited medications during the study
  • Other known active viral or bacterial infection at the time of screening, such as influenza
  • Any medical condition or laboratory abnormality that, in the opinion of the investigator, could jeopardize the safety of the patient or affect patient compliance or safety/efficacy observations during the study
  • COVID-19 vaccination within ≤ 40-days prior to enrollment (second dose if applicable)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
216 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    The dose and regimen of the placebo will match that of AT-527.

    Drug: Placebo

  • Experimental
    RO7496998 (AT-527)

    Orally administered, 550 mg twice daily (BID) for 5 days

    Drug: RO7496998

Interventions

  • 275 mg tablets

    Also known as: AT-527

  • DrugPlacebo

    Matching tablets

06

What researchers measure

Primary outcomes

  1. Time to Alleviation or Improvement of COVID-19 Symptoms (21.5 Hours)

    COVID-19 symptoms will be evaluated using the COVID-19 Symptom Diary (questions 1-12). The severity of each COVID-19 symptom will be recorded on a Likert scale (i.e none/mild/moderate/severe). The time to alleviation or improvement of COVID-19 symptoms is defined as follows: for new symptoms, it is defined as the length of time taken from randomization to the point at which a Score of 0 or 1 has been maintained for a duration of at least 21.5 hours. For preexisting symptoms, it is defined as the time from randomization to when a patient's symptoms have been maintained or improved (requires at least a single category improvement from baseline on the COVID-19 Symptom Diary Likert scale) for a duration of 21.5 hours.

    Time frame: Up to 29 days

Secondary outcomes

  1. Time to Alleviation or Improvement of COVID-19 Symptoms (43 Hours)

    COVID-19 symptoms will be evaluated using the COVID-19 Symptom Diary (questions 1-12). The severity of each COVID-19 symptom will be recorded on a Likert scale (i.e none/mild/moderate/severe). The time to alleviation or improvement of COVID-19 symptoms is defined as follows: for new symptoms, it is defined as the length of time taken from randomization to the point at which a Score of 0 or 1 has been maintained for a duration of at least 43 hours. For preexisting symptoms, it is defined as the time from randomization to when a patient's symptoms have been maintained or improved (requires at least a single category improvement from baseline on the COVID-19 Symptom Diary Likert scale) for a duration of 43 hours.

    Time frame: Up to 29 days

  2. Time to Alleviation of COVID-19 Symptoms (21.5 Hours)

    Time from randomization to the point at which the following criterion is met and maintained for at least 21.5 hours. - Score of 0 or 1 on Items 1-12 of the COVID-19 Symptom Diary.

    Time frame: Up to 29 days

  3. Time to Alleviation of COVID-19 Symptoms (43 Hours)

    Time from randomization to the point at which the following criterion is met and maintained for at least 43 hours. - Score of 0 or 1 on Items 1-12 of the COVID-19 Symptom Diary.

    Time frame: Up to 29 days

  4. Time to One-Category Improvement of Baseline Presenting COVID-19 Symptoms

    Time from randomization to the point at which symptoms (Items 1-12 of the COVID-19 Symptom Diary) have improved by at least one category from baseline on the COVID-19 Symptom Diary Likert scale, maintained for at least 21.5 hours.

    Time frame: Up to 29 days

  5. Time to Alleviation of Individual Symptoms

    Time from randomization to the point at which the following criterion is met and maintained (for each individual symptom) for at least 21.5 hours. - Score of 0 or 1 for Items 1-14 of the COVID-19 Symptom Diary

    Time frame: Up to 29 days

  6. Percentage of Participants Requiring Hospitalization for COVID-19

    Hospitalizations for COVID-19 are defined as SAEs for which the investigator has cited that the suspected cause was the disease under study and where there is a non-missing hospital admission date.

    Time frame: Up to Day 33 visit

  7. Percentage of Participants With Greater Than or Equal to 1 COVID-19 Related Medically Attended Visit

    Medically attended visit is defined as hospitalization, emergency room (ER) visit, urgent care visit, physician's office visit, or telemedicine visit, with the primary reason for the visit being COVID-19.

    Time frame: Up to Day 33 visit

  8. Duration of Fever

    Time to return to an afebrile state (temperature ≤ 37.5°C) maintained for at least 21.5 hours.

    Time frame: Up to 29 days

  9. Percentage of Participants With COVID-19 Related Complications

    COVID-related complications are defined as death, hospitalization, pneumonia, sepsis, coagulopathy, pericarditis/myocarditis and cardiac failure. Pneumonia, acute respiratory failure, sepsis, coagulopathy, pericarditis/myocarditis, and cardiac failure were adjudicated per blinded manual medical review of events by an internal adjudication team before study readout.

    Time frame: Up to Day 33 visit

  10. Percentage of Participants With Any Post-Treatment Infection

    Post-treatment infections were defined as any treatment-emergent adverse event with a primary system organ class of infections and infestations.

    Time frame: Up to Day 33 visit

  11. Change From Baseline in the Amount of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus RNA

    SARS-CoV-2 virus RNA will be measured by reverse-transcriptase quantitative polymerase chain reaction (RT-qPCR)

    Time frame: Baseline and on Days 3, 5, 7 and 14

  12. Time to Cessation of SARS-CoV-2 Viral Shedding

    Defined as time from randomization to the first time when a negative qualitative virus RNA by RT-PCR test result is obtained.

    Time frame: Up to 14 days

  13. Percentage of Participants Positive for SARS-CoV-2 Virus RNA at Specified Timepoints

    Defined as percentage of participants with a positive qualitative virus RNA by RT-PCR.

    Time frame: Baseline and on Days 3, 5, 7 and 14

  14. Area Under the Curve (AUC) in the Amount of SARS-CoV-2 Virus RNA

    Time frame: Day 1 prior to dosing, Day 3, Day 5, Day 7 and Day 14

  15. Percentage of Participants With Adverse Events (AEs)

    Time frame: Up to Day 33 visit

  16. Plasma Concentration of AT-511 at Specified Timepoints

    AT-511 is the free base form of RO7496998 (AT-527).

    Time frame: Up to 7 days

  17. Plasma Concentration of AT-551 at Specified Timepoints

    AT-511 is the free base form of RO7496998 (AT-527). Major metabolites are AT-551, AT-229, and AT-273 (a surrogate for the intracellular concentration of the active triphosphate metabolite AT-9010)

    Time frame: Up to 7 days

  18. Plasma Concentration of AT-229 at Specified Timepoints

    AT-511 is the free base form of RO7496998 (AT-527). Major metabolites are AT-551, AT-229, and AT-273 (a surrogate for the intracellular concentration of the active triphosphate metabolite AT-9010)

    Time frame: Up to 7 days

  19. Plasma Concentration of AT-273 at Specified Timepoints

    AT-511 is the free base form of RO7496998 (AT-527). Major metabolites are AT-551, AT-229, and AT-273 (a surrogate for the intracellular concentration of the active triphosphate metabolite AT-9010)

    Time frame: Up to 7 days

07

Results

Posted Jan 5, 2024
Limitations and caveats
The study was terminated with only 16% of the planned sample size.

Participant flow

Participants were non-hospitalized, with mild to moderate COVID-19, with or without risk factors for severe disease.

Participant flow — Overall Study
MilestonePlaceboRO7496998 (AT-527)
Started73143
Received treatment71141
Completed68138
Not completed55
Withdrew: Withdrawal by subject33
Withdrew: Lost to follow-up01
Withdrew: Adverse event21

Outcome measures

PrimaryTime to Alleviation or Improvement of COVID-19 Symptoms (21.5 Hours)

COVID-19 symptoms will be evaluated using the COVID-19 Symptom Diary (questions 1-12). The severity of each COVID-19 symptom will be recorded on a Likert scale (i.e none/mild/moderate/severe). The time to alleviation or improvement of COVID-19 symptoms is defined as follows: for new symptoms, it is defined as the length of time taken from randomization to the point at which a Score of 0 or 1 has been maintained for a duration of at least 21.5 hours. For preexisting symptoms, it is defined as the time from randomization to when a patient's symptoms have been maintained or improved (requires at least a single category improvement from baseline on the COVID-19 Symptom Diary Likert scale) for a duration of 21.5 hours.

Time frame:
Up to 29 days
Reported as:
Median · hours
Time to Alleviation or Improvement of COVID-19 Symptoms (21.5 Hours)
hoursPlaceboRO7496998 (AT-527)
Time to Alleviation or Improvement of COVID-19 Symptoms (21.5 Hours)73.7 (47.1 to 105.8)94.5 (68.1 to 131.7)
SecondaryTime to Alleviation or Improvement of COVID-19 Symptoms (43 Hours)

COVID-19 symptoms will be evaluated using the COVID-19 Symptom Diary (questions 1-12). The severity of each COVID-19 symptom will be recorded on a Likert scale (i.e none/mild/moderate/severe). The time to alleviation or improvement of COVID-19 symptoms is defined as follows: for new symptoms, it is defined as the length of time taken from randomization to the point at which a Score of 0 or 1 has been maintained for a duration of at least 43 hours. For preexisting symptoms, it is defined as the time from randomization to when a patient's symptoms have been maintained or improved (requires at least a single category improvement from baseline on the COVID-19 Symptom Diary Likert scale) for a duration of 43 hours.

Time frame:
Up to 29 days
Reported as:
Median · hours
Time to Alleviation or Improvement of COVID-19 Symptoms (43 Hours)
hoursPlaceboRO7496998 (AT-527)
Time to Alleviation or Improvement of COVID-19 Symptoms (43 Hours)79.6 (55.7 to 108.2)109.5 (83.8 to 147.5)
SecondaryTime to Alleviation of COVID-19 Symptoms (21.5 Hours)

Time from randomization to the point at which the following criterion is met and maintained for at least 21.5 hours. - Score of 0 or 1 on Items 1-12 of the COVID-19 Symptom Diary.

Time frame:
Up to 29 days
Reported as:
Median · hours
Time to Alleviation of COVID-19 Symptoms (21.5 Hours)
hoursPlaceboRO7496998 (AT-527)
Time to Alleviation of COVID-19 Symptoms (21.5 Hours)73.7 (47.1 to 105.8)94.5 (68.1 to 131.7)
SecondaryTime to Alleviation of COVID-19 Symptoms (43 Hours)

Time from randomization to the point at which the following criterion is met and maintained for at least 43 hours. - Score of 0 or 1 on Items 1-12 of the COVID-19 Symptom Diary.

Time frame:
Up to 29 days
Reported as:
Median · hours
Time to Alleviation of COVID-19 Symptoms (43 Hours)
hoursPlaceboRO7496998 (AT-527)
Time to Alleviation of COVID-19 Symptoms (43 Hours)79.6 (55.7 to 108.2)109.5 (83.8 to 147.5)
SecondaryTime to One-Category Improvement of Baseline Presenting COVID-19 Symptoms

Time from randomization to the point at which symptoms (Items 1-12 of the COVID-19 Symptom Diary) have improved by at least one category from baseline on the COVID-19 Symptom Diary Likert scale, maintained for at least 21.5 hours.

Time frame:
Up to 29 days
Reported as:
Median · hours
Time to One-Category Improvement of Baseline Presenting COVID-19 Symptoms
hoursPlaceboRO7496998 (AT-527)
Time to One-Category Improvement of Baseline Presenting COVID-19 Symptoms70.9 (41.8 to 91.8)81.5 (60.5 to 119.9)
SecondaryTime to Alleviation of Individual Symptoms

Time from randomization to the point at which the following criterion is met and maintained (for each individual symptom) for at least 21.5 hours. - Score of 0 or 1 for Items 1-14 of the COVID-19 Symptom Diary

Time frame:
Up to 29 days
Reported as:
Median · hours
Time to Alleviation of Individual Symptoms
hoursPlaceboRO7496998 (AT-527)
Nasal Congestion or Runny Nose36.4 (23.4 to 60.6)37.3 (23.4 to 57.6)
Sore Throat45.6 (23.4 to 75.1)33.2 (20.9 to 54.3)
Cough37.6 (26.8 to 118.7)49.5 (28.4 to 106.4)
Shortness of Breath24.0 (11.8 to 106.8)47.5 (32.4 to 96.8)
Muscle or Body Aches35.3 (14.3 to 59.4)44.9 (33.1 to 53.0)
Fatigue66.6 (36.5 to 118.9)61.3 (47.1 to 108.1)
Headache23.2 (14.5 to 41.8)41.4 (24.4 to 59.5)
Chills/Sweats36.0 (22.5 to 57.6)39.0 (28.4 to 50.5)
Feeling Hot or Feverish24.6 (16.4 to 66.7)36.2 (19.7 to 61.4)
Nausea31.4 (11.1 to NA)43.5 (22.6 to 73.4)
Vomiting20.1 (16.4 to NA)33.0 (NA to NA)
Diarrhea17.6 (14.9 to 73.6)66.7 (19.8 to 107.2)
Sense of Smell132.6 (84.3 to 229.0)104.9 (72.6 to 206.0)
Sense of Taste128.9 (84.3 to 202.2)155.7 (52.5 to 371.7)
SecondaryPercentage of Participants Requiring Hospitalization for COVID-19

Hospitalizations for COVID-19 are defined as SAEs for which the investigator has cited that the suspected cause was the disease under study and where there is a non-missing hospital admission date.

Time frame:
Up to Day 33 visit
Reported as:
Number · percentage of participants
Percentage of Participants Requiring Hospitalization for COVID-19
percentage of participantsPlaceboRO7496998 (AT-527)
Percentage of Participants Requiring Hospitalization for COVID-1910.0 (1.25 to 18.75)2.9 (0.00 to 6.51)
SecondaryPercentage of Participants With Greater Than or Equal to 1 COVID-19 Related Medically Attended Visit

Medically attended visit is defined as hospitalization, emergency room (ER) visit, urgent care visit, physician's office visit, or telemedicine visit, with the primary reason for the visit being COVID-19.

Time frame:
Up to Day 33 visit
Reported as:
Number · percentage of participants
Percentage of Participants With Greater Than or Equal to 1 COVID-19 Related Medically Attended Visit
percentage of participantsPlaceboRO7496998 (AT-527)
Percentage of Participants With Greater Than or Equal to 1 COVID-19 Related Medically Attended Visit14.3 (4.20 to 24.37)10.2 (4.05 to 16.38)
SecondaryDuration of Fever

Time to return to an afebrile state (temperature ≤ 37.5°C) maintained for at least 21.5 hours.

Time frame:
Up to 29 days
Reported as:
Median · hours
Duration of Fever
hoursPlaceboRO7496998 (AT-527)
Duration of Fever47.3 (12.6 to 82.2)55.7 (25.9 to 96.4)
SecondaryPercentage of Participants With COVID-19 Related Complications

COVID-related complications are defined as death, hospitalization, pneumonia, sepsis, coagulopathy, pericarditis/myocarditis and cardiac failure. Pneumonia, acute respiratory failure, sepsis, coagulopathy, pericarditis/myocarditis, and cardiac failure were adjudicated per blinded manual medical review of events by an internal adjudication team before study readout.

Time frame:
Up to Day 33 visit
Reported as:
Number · percentage of participants
Percentage of Participants With COVID-19 Related Complications
percentage of participantsPlaceboRO7496998 (AT-527)
Percentage of Participants With COVID-19 Related Complications10.0 (1.25 to 18.75)4.4 (0.10 to 8.66)
SecondaryPercentage of Participants With Any Post-Treatment Infection

Post-treatment infections were defined as any treatment-emergent adverse event with a primary system organ class of infections and infestations.

Time frame:
Up to Day 33 visit
Reported as:
Number · percentage of participants
Percentage of Participants With Any Post-Treatment Infection
percentage of participantsPlaceboRO7496998 (AT-527)
Percentage of Participants With Any Post-Treatment Infection14.3 (4.20 to 24.37)9.5 (3.51 to 15.47)
SecondaryChange From Baseline in the Amount of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus RNA

SARS-CoV-2 virus RNA will be measured by reverse-transcriptase quantitative polymerase chain reaction (RT-qPCR)

Time frame:
Baseline and on Days 3, 5, 7 and 14
Reported as:
Mean · log10 copies/mL
Change From Baseline in the Amount of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus RNA
log10 copies/mLPlaceboRO7496998 (AT-527)
Baseline6.49 ± 1.616.59 ± 1.54
Day 3-1.05 ± 1.06-1.07 ± 1.16
Day 5-2.24 ± 1.40-2.01 ± 1.50
Day 7-3.10 ± 1.38-2.98 ± 1.66
Day 14-4.21 ± 1.64-4.25 ± 1.64
SecondaryTime to Cessation of SARS-CoV-2 Viral Shedding

Defined as time from randomization to the first time when a negative qualitative virus RNA by RT-PCR test result is obtained.

Time frame:
Up to 14 days
Reported as:
Median · days
Time to Cessation of SARS-CoV-2 Viral Shedding
daysPlaceboRO7496998 (AT-527)
Time to Cessation of SARS-CoV-2 Viral Shedding13.0 (12.8 to NA)13.0 (13.0 to 13.1)
SecondaryPercentage of Participants Positive for SARS-CoV-2 Virus RNA at Specified Timepoints

Defined as percentage of participants with a positive qualitative virus RNA by RT-PCR.

Time frame:
Baseline and on Days 3, 5, 7 and 14
Reported as:
Number · percentage of participants
Percentage of Participants Positive for SARS-CoV-2 Virus RNA at Specified Timepoints
percentage of participantsPlaceboRO7496998 (AT-527)
Baseline97.1100
Day 398.596.4
Day 589.791.9
Day 774.676.3
Day 1443.934.4
SecondaryArea Under the Curve (AUC) in the Amount of SARS-CoV-2 Virus RNA
Time frame:
Day 1 prior to dosing, Day 3, Day 5, Day 7 and Day 14
Reported as:
Mean · log10 copies/mL*hour
Area Under the Curve (AUC) in the Amount of SARS-CoV-2 Virus RNA
log10 copies/mL*hourPlaceboRO7496998 (AT-527)
Area Under the Curve (AUC) in the Amount of SARS-CoV-2 Virus RNA1122.39 ± 339.701174.30 ± 377.49
SecondaryPercentage of Participants With Adverse Events (AEs)
Time frame:
Up to Day 33 visit
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs)
percentage of participantsPlaceboRO7496998 (AT-527)
Percentage of Participants With Adverse Events (AEs)36.639.0
SecondaryPlasma Concentration of AT-511 at Specified Timepoints

AT-511 is the free base form of RO7496998 (AT-527).

Time frame:
Up to 7 days
Reported as:
Mean · nanograms per milliliter (ng/mL)
Plasma Concentration of AT-511 at Specified Timepoints
nanograms per milliliter (ng/mL)RO7496998 (AT-527)
Day 1, 0 hour17.4 ± 158.6
Day 1, 1 hour1456.8 ± 1757.7
Day 1, 2 hours1029.3 ± 1085.5
Day 1, 4 hours206.3 ± 289.5
Day 5, 0 hour52.8 ± 271.0
Day 5, 1 hour1659.0 ± 2213.9
Day 5, 2 hours1934.5 ± 2210.6
Day 5, 4 hours202.3 ± 310.7
Day 5, 8 hours8.8 ± 9.5
Day 5, 48 hours4.6 ± 40.9
SecondaryPlasma Concentration of AT-551 at Specified Timepoints

AT-511 is the free base form of RO7496998 (AT-527). Major metabolites are AT-551, AT-229, and AT-273 (a surrogate for the intracellular concentration of the active triphosphate metabolite AT-9010)

Time frame:
Up to 7 days
Reported as:
Mean · nanograms per milliliter (ng/mL)
Plasma Concentration of AT-551 at Specified Timepoints
nanograms per milliliter (ng/mL)RO7496998 (AT-527)
Day 1, 0 hour1.9 ± 12.2
Day 1, 1 hour166.9 ± 209.8
Day 1, 2 hours335.7 ± 257.6
Day 1, 4 hours195.0 ± 146.4
Day 5, 0 hour49.1 ± 65.0
Day 5, 1 hour150.2 ± 144.5
Day 5, 2 hours213.6 ± 201.7
Day 5, 4 hours138.8 ± 136.2
Day 5, 8 hours27.5 ± 17.5
Day 5, 48 hours2.6 ± 5.2
SecondaryPlasma Concentration of AT-229 at Specified Timepoints

AT-511 is the free base form of RO7496998 (AT-527). Major metabolites are AT-551, AT-229, and AT-273 (a surrogate for the intracellular concentration of the active triphosphate metabolite AT-9010)

Time frame:
Up to 7 days
Reported as:
Mean · nanograms per milliliter (ng/mL)
Plasma Concentration of AT-229 at Specified Timepoints
nanograms per milliliter (ng/mL)RO7496998 (AT-527)
Day 1, 0 hour2.2 ± 18.4
Day 1, 1 hour123.6 ± 172.5
Day 1, 2 hours507.8 ± 497.5
Day 1, 4 hours354.4 ± 259.2
Day 5, 0 hour367.8 ± 259.1
Day 5, 1 hour418.0 ± 257.6
Day 5, 2 hours454.3 ± 331.7
Day 5, 4 hours490.1 ± 296.4
Day 5, 8 hours279.6 ± 176.0
Day 5, 48 hours118.7 ± 127.2
SecondaryPlasma Concentration of AT-273 at Specified Timepoints

AT-511 is the free base form of RO7496998 (AT-527). Major metabolites are AT-551, AT-229, and AT-273 (a surrogate for the intracellular concentration of the active triphosphate metabolite AT-9010)

Time frame:
Up to 7 days
Reported as:
Mean · nanograms per milliliter (ng/mL)
Plasma Concentration of AT-273 at Specified Timepoints
nanograms per milliliter (ng/mL)RO7496998 (AT-527)
Day 1, 0 hour0.7 ± 2.5
Day 1, 1 hour15.5 ± 26.9
Day 1, 2 hours135.1 ± 136.2
Day 1, 4 hours173.5 ± 120.6
Day 5, 0 hour149.8 ± 78.1
Day 5, 1 hour141.7 ± 72.7
Day 5, 2 hours108.8 ± 61.0
Day 5, 4 hours172.7 ± 129.2
Day 5, 8 hours118.6 ± 80.2
Day 5, 48 hours48.4 ± 32.7

Adverse events

Collected over up to the Day 33 visit. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/71 (0%)7/71 (9.9%)5/71 (7%)
AT-5270/141 (0%)5/141 (3.5%)11/141 (7.8%)
Most frequent serious events
Most frequent serious events
EventPlaceboAT-527
COVID-19 pneumoniaInfections and infestations4/711/141
COVID-19Infections and infestations3/712/141
Pneumonia staphylococcalInfections and infestations0/711/141
Acute kidney injuryRenal and urinary disorders0/711/141
HypoxiaRespiratory, thoracic and mediastinal disorders0/711/141
PneumothoraxRespiratory, thoracic and mediastinal disorders0/711/141
Respiratory failureRespiratory, thoracic and mediastinal disorders0/711/141
Most frequent other events
Most frequent other events
EventPlaceboAT-527
HeadacheNervous system disorders5/714/141
Back painMusculoskeletal and connective tissue disorders0/718/141

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboRO7496998 (AT-527)Total
Mean41.7 ± 14.941.1 ± 13.241.3 ± 13.7
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRO7496998 (AT-527)Total
Female326294
Male4181122
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboRO7496998 (AT-527)Total
American Indian or Alaska Native6915
Asian142640
Native Hawaiian or Other Pacific Islander101
Black or African American134
White50105155
More than one race000
Unknown or Not Reported101
Number of COVID-19 Symptoms Present at Baseline
Number of COVID-19 Symptoms Present at Baseline(Number of Covid-19 Symptoms)PlaceboRO7496998 (AT-527)Total
Mean7.85 ± 2.587.92 ± 2.747.90 ± 2.68
08

Study locations

50 sites
  • Instituto Ave Pulmo
    Mar Del Plata, B7602DCK, Argentina
  • Maison Médicale La Brèche
    Châtelineau, 6200, Belgium
  • Private Practice Dr Jean Benoit Martinot
    Erpent, 5101, Belgium
  • Medif
    Gozée, 6534, Belgium
  • L2 Ip Instituto de Pesquisas Clinicas Ltda ME; Centro Medico Hospitalar
    Brasilia, DF 70200-730, Brazil
  • Chronos Pesquisa Clinica
    Taguatinga, DF 72145-450, Brazil
  • Hospital Agamenon Magalhães
    Recife, PE 52051-380, Brazil
  • Hospital Nossa Senhora das Graças
    Curitiba, PR 80810-040, Brazil
  • Conjunto Hospitalar do Mandaqui
    Sao Paulo, SP 02401-400, Brazil
  • Aalborg Universitetshospital
    Aalborg, 9000, Denmark
  • Rigshospitalet Copenhagen University Hospital
    Copenhagen, DK-2100, Denmark
  • Praxis am Ebertplatz
    Köln, 50668, Germany
  • Higashiosaka city Medical Center
    Higashiosaka-Shi, 578-0947, Japan
  • Rinku General Medical Center
    Izumisano, 598-0048, Japan
  • Sagamihara Kyodo Hospital
    Kanagawa, 252-5188, Japan
  • Misyuku hospital
    Meguro-Ku, 153-0051, Japan
  • IUHW Narita Hospital
    Narita, 286-8520, Japan
  • Houjin Syadan Kouhoukai Takagi Hospital
    Okawa-Shi, 831-0016, Japan
  • Okayama City Hospital
    Okayama, 700-8557, Japan
  • Ome Municipal General Hospital
    Ome-Shi, 198-0042, Japan
  • National Hospital Organization Kinki-Chuo Chest Medical Center
    Sakai-shi, 591-8555, Japan
  • Tokyo Shinagawa Hospital Medical Corporation Association Tokyokyojuno-kai
    Shinagawa, 140-8522, Japan
  • Edogawa Medicare Hospital
    Tokyo, 133-0071, Japan
  • Center Hospital of the National Center for Global Health and Medicine
    Tokyo, 162-0052, Japan
  • Tokyo Medical University Hachioji Medical Center
    Tokyo, 193-0998, Japan
  • CIMAB SA de CV
    Torreón, Coahuila 27000, Mexico
  • Panamerican Clinical Research S.A de C.V.
    Guadalajara, Jalisco 44670, Mexico
  • Clinstile S.A de C.V.
    Mexico City, Mexico CITY (federal District) 06700, Mexico
  • PanAmerican Clinical Research, Querétaro
    Queréaro, Queretaro 76230, Mexico
  • Instituto Jalisciense de Investigacion Clinica S.A. de C.V.
    Guadalajara, 44100, Mexico
  • Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
    Mexico, Mexico
  • Unidade Local de Saude de Matosinhos SA
    Matosinhos, 4454-509, Portugal
  • Prof. Dr. Matei Bals Institute of Infectious Diseases
    Bucuresti, 021105, Romania
  • County Hospital Caracal
    Caracal, 235200, Romania
  • Sibiu Emergency Clinical County Hospital
    Sibiu, 550245, Romania
  • Hôpital Universitaire de Genève (HUG)
    Genève, 1211, Switzerland
  • Universitätsspital Zürich
    Zürich, 8091, Switzerland
  • Gazi Universitesi Tip Fakultesi
    Ankara, 06100, Turkey
  • Ege University Medical Faculty
    Izmir, 35100, Turkey
  • Karadeniz Technical University Faculty of Medicine
    Trabzon, 61080, Turkey
  • Ankara University Medical Faculty - PPDS
    Çankaya, 06590, Turkey
  • Municipal Non-profit Enterprise ?City Clinical Hospital #13? of Kharkiv City Council
    Kharkiv, Kharkiv Governorate 61124, Ukraine
  • Public Non-Profit Enterprise ?City Outpatient Clinic #9? of Kharkiv City Council
    Kharkiv, Kharkiv Governorate 61172, Ukraine
  • CNPE City Clinical Hospital #6 of DCC
    Dnipro, Kholm Governorate 49074, Ukraine
  • Medical Center LLC "Harmony of Beauty"
    Kyiv, KIEV Governorate 01135, Ukraine
  • CNE Kyiv City Clinical Hospital#1 of Exec. Body
    Kyiv, KIEV Governorate 02091, Ukraine
  • Kyiv Railway Clinical Hospital No2 of Branch Health Center of the JSC Ukrainian Rail
    Kyiv, KIEV Governorate 03049, Ukraine
  • Polyclinic of Center of Medical Service and Rehabilitation of State JSHC Artem
    Kyiv, KIEV Governorate 04050, Ukraine
  • Communal Non-Commercial Enterprise Vinnytsia City Clinical Hospital 1
    Vinnytsya, Podolia Governorate, Ukraine
  • Communal Non-Profit Enterprise City Hospital #7 of Zaporizhzhia City Council
    Zaporizhzhia, Tavria Okruha 69118, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm)

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2021 to primary completion in Dec 2021, 7 months.

Results were first posted in Jan 2024, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2021
First posted
May 17, 2021
StartActual
Apr 28, 2021
Primary completionActual
Dec 2, 2021
CompletionActual
Dec 2, 2021
Results first posted
Jan 5, 2024
Last update
Jan 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04889040
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
May 17, 2021
Start date
Apr 28, 2021
Primary completion
Dec 2, 2021
Completion
Dec 2, 2021
Results posted
Jan 5, 2024
Last update
Jan 5, 2024

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AT-511

Start the discussion